The aim of this study was to develop and validate a computer simulation model for coronary heart disease (CHD) in type 2 diabetes mellitus (T2DM) that reflects current medical and surgical treatments.
Research Design and Methods:
We modified the structure of the CHD submodel in the Michigan Model for Diabetes to allow for revascularization procedures before and after first myocardial infarction, for repeat myocardial infarctions and repeat revascularization procedures, and for congestive heart failure. Transition probabilities that reflect the direct effects of medical and surgical therapies on outcomes were derived from the literature and calibrated to recently published population-based epidemiologic studies and randomized controlled clinical trials. Monte Carlo techniques were used to implement a discrete-state and discrete-time multistate microsimulation model. Performance of the model was assessed using internal and external validation. Simple regression analysis (simulated outcome=b0+b1×published outcome) was used to evaluate the validation results.
Results:
For the 21 outcomes in the six studies used for internal validation, R2 was 0.99, and the slope of the regression line was 0.98. For the 16 outcomes in the five studies used for external validation, R2 was 0.81, and the slope was 0.84.
Conclusions:
Our new computer simulation model predicted the progression of CHD in patients with T2DM and will be incorporated into the Michigan Model for Diabetes to assess the cost-effectiveness of alternative strategies to prevent and treat T2DM.
Get full access to this article
View all access options for this article.
References
1.
KumbhaniDJ, FonarowGC, CannonCP, HernandezAF, PetersonED, PeacockF, LaskeyWK, DeedwaniaP, Grau-SepulvedaM, SchwammLH, BhattDL: Temporal trends for secondary prevention measures among patients hospitalized with coronary artery disease. Am J Med, 2015; 128:426.e1–e9.
2.
HeadSJ, KieserTM, FalkV, HuysmansHA, KappeteinAP: Coronary artery bypass grafting: Part 1—the evolution over the first 50 years. Eur Heart J, 2013; 34:2862–2872.
3.
GerberY, RihalCS, SundtTM3rd, KillianJM, WestonSA, TherneauTM, RogerVL: Coronary revascularization in the community. A population-based study, 1990 to 2004. J Am Coll Cardiol, 2007; 50:1223–1229.
4.
BalmerF, RotterM, TogniM, PfiffnerD, ZeiherAM, MaierW, MeierB; Working Group Interventional Cardiology, Coronary Pathophysiology of the European Society of Cardiology: Percutaneous coronary interventions in Europe 2000. Int J Cardiol, 2005; 101:457–463.
5.
UlrichMR, BrockDM, ZiskindAA: Analysis of trends in coronary artery bypass grafting and percutaneous coronary intervention rates in Washington State from 1987 to 2001. Am J Cardiol, 2003; 92:836–839.
6.
GreggEW, LiY, WangJ, BurrowsNR, AliMK, RolkaD, WilliamsDE, GeissL: Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med, 2014; 370:1514–1523.
7.
RoffiM, RadovanovicD, ErneP, UrbanP, WindeckerS, EberliFR; AMIS Plus Investigator: Gender-related mortality trends among diabetic patients with ST-segment elevation myocardial infarction: insights from a nationwide registry 1997–2010. Eur Heart J, 2013; 2:342–349.
8.
Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet, 2000; 355:253–259.
9.
ChengJ, ZhangW, ZhangX, HanF, LiX, HeX, LiQ, ChenJ: Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med, 2014; 174:773–785.
10.
FreemantleN, ClelandJ, YoungP, MasonJ, HarrisonJ: β Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ, 1999; 318:1730–1737.
11.
GottliebSS, McCarterRJ, VogelRA: Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med, 1998; 339:489–497.
12.
Garcia-EgidoA, AndreyJL, PuertoJL, ArandaRM, PedrosaMJ, López-SáezJB, RosetyM, GomezF: Beta-blocker therapy and prognosis of heart failure patients with new-onset diabetes mellitus. Int J Clin Pract, 2015; 69:550–559.
13.
Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo controlled trial. Lancet, 2003; 361:2005–2016.
14.
Centers for Disease Control and Prevention: National Diabetes Fact Sheet, 2011. Atlanta: Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, 2011.
15.
International Diabetes Federation: The IDF Diabetes Atlas, 5th ed., 2012 update. Brussels: International Diabetes Federation, 2012.
16.
McEwenLN, KimC, KarterAJ, HaanMN, GhoshD, LantzPM, MangioneCM, ThompsonTJ, HermanWH: Risk factors for mortality among patients with diabetes: the Translating Research Into Action for Diabetes (TRIAD) Study. Diabetes Care, 2007; 30:1736–1741.
17.
McEwenLN, KarterAJ, WaitzfelderBE, CrossonJC, MarreroDG, MangioneCM, HermanWH: Predictors of mortality over 8 years in type 2 diabetic patients: Translating Research Into Action for Diabetes (TRIAD). Diabetes Care, 2012; 35:1301–1309.
18.
ZhouH, IsamanDJ, MessingerS, BrownMB, KleinR, BrandleM, HermanWH: A computer simulation model of diabetes progression, quality of life, and cost. Diabetes Care, 2005; 28:2856–2863.
19.
StevensRJ, KothariV, AdlerAI, StrattonIM: The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci, 2001; 101:671–679.
20.
Mount Hood 4 Modeling Group: Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care, 2007; 30:1638–1646.
21.
BrownJB, RussellA, ChanW, PedulaK, AickinM: The global diabetes model: user friendly version 3.0. Diabetes Res Clin Pr, 2000; 50(Suppl 3):S15–S46.
22.
BagustA, HopkinsonPK, MaierW, CurrieCJ: An economic model of the long-term health care burden of Type II diabetes. Diabetologia, 2001; 44:2140–2155.
23.
The CDC Diabetes Cost-effectiveness Group: Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA, 2002; 287:2542–2551.
24.
McEwanP, PetersJR, BergenheimK, CurrieCJ: Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). Curr Med Res Opin, 2006; 22:121–129.
25.
PalmerAJ, RozeS, ValentineWJ, MinshallME, FoosV, LuratiFM, LammertM, SpinasGA: The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin, 2004; 20(Suppl 1):S5–S26.
26.
MuellerE, Maxion-BergemannS, Gultyaev WalzerS, FreemantleN, MathieuC, BolinderB, GerberR, KvaszM, BergemannR: Development and validation of the Economic Assessment of Glycemic Control and Long-Term Effects of Diabetes (EAGLE) model. Diabetes Technol Ther, 2006; 8:219–236.
27.
BertramMY, LimSS, BarendregtJJ, VosT: Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care. Diabetologia, 2010; 53:875–881.
28.
ClarkePM, GrayAM, BriggsA, FarmerAJ, FennP, StevensRJ, MatthewsDR, StrattonIM, HolmanRR; UK Prospective Diabetes Study (UKDPS) Group: A model to estimate the life time health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia, 2004; 47:1747–1759.
29.
TildenDP, MarizS, O'Bryan-TearG, BottomleyJ, DiamantopoulosA: A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. Pharmacoeconomics, 2007; 25:39–54.
30.
PalmerAJ; Mount Hood 5 Modeling Group, ClarkeP, GrayA, LealJ, LloydA, GrantD, PalmerJ, FoosV, LamotteM, HermannW, BarhakJ, WillisM, ColemanR, ZhangP, McEwanP, Betz BrownJ, GerdthamU, HuangE, BriggsA, CarlssonKS, ValentineW: Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting. Value Health, 2013; 16:670–685.
31.
TarrideJE, HopkinsR, BlackhouseG, BowenJM, BischofM, Von KeyserlingkC, O'ReillyD, XieF, GoereeR: A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment. Pharmacoeconomics, 2010; 28:255–277.
32.
LundqvistA, CarlssonKS, JohansenP, AnderssonE, WillisM: Validation of the IHE cohort model of type 2 diabetes and the impact of choice of macrovascular risk equations. PLoS One, 2014; 9:e110235.
33.
Ahmad KiadaliriA, GerdthamU-G, NilssonP, EliassonB, GudbjörnsdottirS, CarlssonKS: Towards renewed health economic simulation of type 2 diabetes: risk equations for first and second cardiovascular events from Swedish register data. PLoS One, 2013; 8:e62650.
34.
HayesAJ, LealJ, GrayAM, HolmanRR, ClarkePM: UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia, 2013; 56:1925–1933.
35.
UnalB, CapewellS, CritchleyJA: Coronary heart disease policy models: a systematic review. BMC Public Health, 2006; 6:213.
36.
FriedLP, BorhaniNO, EnrightP, FurbergCD, GardinJM, KronmalRA, KullerLH, ManolioTA, MittelmarkMB, NewmanA: The Cardiovascular Health Study: design and rationale. Ann Epidemiol, 1991; 1:263–276.
37.
PignoneM, AlbertsMJ, ColwellJA, CushmanM, InzucchiSE, MukherjeeD, RosensonRS, WilliamsCD, WilsonPW, KirkmanMS: Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol, 2010; 55:2878–2886.
FranklinK, GoldbergRJ, SpencerF, KleinW, BudajA, BriegerD, MarreM, StegPG, GowdaN, GoreJM; GRACE Investigators: Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. Arch Intern Med, 2004; 164:1457–1463.
40.
JensenLO, MaengM, ThayssenP, TilstedHH, TerkelsenCJ, KaltoftA, LassenJF, HansenKN, RavkildeJ, ChristiansenEH, MadsenM, SørensenHT, ThuesenL: Influence of diabetes mellitus on clinical outcomes following primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Am J Cardiol, 2012; 109:629–635.
41.
AvogaroA, GiordaC, MagginiM, MannucciE, RaschettiR, LombardoF, Spila-AlegianiS, TurcoS, VelussiM, FerranniniE; Diabetes and Informatics Study Group, Association of Clinical Diabetologists, Istituto Superiore di Sanità: Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care, 2007; 30:1241–1247.
42.
ChaitmanBR, HardisonRM, AdlerD, GebhartS, GroganM, OcampoS, SopkoG, RamiresJA, SchneiderD, FryeRL; Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group: The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in Type 2 diabetes mellitus with stable ischemic heart disease. Circulation, 2009; 120:2529–2540.
43.
ColeJH, JonesEL, CraverJM, GuytonRA, MorrisDC, DouglasJS, GhazzalZ, WeintraubWS: Outcomes of repeat revascularization in diabetic patients with prior coronary surgery. J Am Coll Cardiol, 2002; 40:1968–1975.
44.
ColhounHM, BetteridgeDJ, DurringtonPN, HitmanGA, NeilHA, LivingstoneSJ, ThomasonMJ, MacknessMI, Charlton-MenysV, FullerJH; CARDS Investigators: Primary prevention of cardiovascular disease with atovarstatin in type 2 diabetes in the collaborative Atorvastati Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet, 2004; 364:685–696.
45.
DeedwaniaPC, AhmedMI, FellerMA, AbanIB, LoveTE, PittB, AhmedA: Impact of diabetes mellitus on outcomes in patients with acute myocardial infarction and systolic heart failure. Eur J Heart Fail, 2011; 13:551–559.
46.
MellbinLG, MalmbergK, NorhammarA, WedelH, RydénL; DIGAMI 2 Investigators. Prognostic implication of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the diabetes mellitus insulin-glucose infusion in acute myocardial infarction (DIGAMI) 2 study. Diabetologia, 2011; 54:1308–1317.
47.
LingmanM, AlbertssonP, HerlitzJ, BergfeldtL, LagerqvistB: The impact of hypertension and diabetes on outcome in patients undergoing percutaneous coronary intervention. Am J Med, 2011; 124:265–275.
48.
DavisWA, ColagiuriS, DavisTM: Comparison of the Framingham and United Kingdom Prospective Diabetes Study cardiovascular risk equations in Australian patients with type 2 diabetes from the Fremantle Diabetes Study. Med J Aust, 2009; 190:180–184.
49.
TaoL, WilsonEC, GriffinSJ, SimmonsRK; ADDITION-Europe Study Team: Performance of the UKPDS outcomes model for prediction of myocardial infarction and stroke in the ADDITION-Europe trial cohort. Value Health, 2013; 16:1074–1080.
50.
ErikssonH, SvardsuddK, LarssonB, OhlsonLO, TibblinG, WelinL, WilhelmsenL: Risk factors for heart failure in the general population: the study of men born in 1913. Eur Heart J, 1989; 10:647–656.
51.
HeJ, OgdenLG, BazzanoLA, VupputuriS, LoriaC, WheltonPK: Risk factors for congestive heart failure in US men and women NHANES I epidemiologic follow-up study. Arch Intern Med, 2001; 161:996–1002.
52.
AntoliniL, BoracchiP, BiganzoliE: A time-dependent discrimination index for survival data. Stat Med, 2005; 24:3927–3944.
53.
WeinsteinMC, O'BrienB, HornbergerJ, JohannessonM, McCabeC, LuceBR; ISPOR Task Force on Good Research Practices—Modeling Studies: Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices—Modeling Studies. Value Health, 2003; 6:9–17.
54.
DuckworthW, AbrairaC, MoritzT, RedaD, EmanueleN, ReavenPD, ZieveFJ, MarksJ, DavisSN, HaywardR, WarrenSR, GoldmanS, McCarrenM, VitekME, HendersonWG, HuangGD; VADT Investigators: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med, 2009; 360:129–139.
55.
The Action to Control Cardiovascular Risk in Diabetes Study Group, GersteinHC, MillerME, ByingtonRP, GoffDCJr, BiggerJT, BuseJB, CushmanWC, GenuthS, Ismail-BeigiF, GrimmRHJr, ProbstfieldJL, Simons-MortonDG, FriedewaldWT: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med, 2008; 358:2545-2559.
56.
KahnSE, LachinJM, ZinmanB, HaffnerSM, AftringRP, PaulG, KravitzBG, HermanWH, VibertiG, HolmanRR; ADOPT Study Group: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med, 2006; 355:2427–2443.
57.
PatelA; ADVANCE Collaborative Group, MacMahonS, ChalmersJ, NealB, WoodwardM, BillotL, HarrapS, PoulterN, MarreM, CooperM, GlasziouP, GrobbeeDE, HametP, HellerS, LiuLS, ManciaG, MogensenCE, PanCY, RodgersA, WilliamsB: Effect of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet, 2007; 370:829–840.
58.
GriffinSJ, Borch-JohnsenK, DaviesMJ, KhuntiK, RuttenGE, SandbækA, SharpSJ, SimmonsRK, van den DonkM, WarehamNJ, LauritzenT: Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomized trial. Lancet, 2011; 378:156–167.
59.
GiorginoF, LeonardiniA, LaviolaL: Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials. Ann N Y Acad Sci, 2013; 1281:36–50.
60.
McMurrayJJV, GersteinHC, HolmanRR, PfefferMA: Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol, 2014; 2:843–851.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
